Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 20
Tirzepatide: 6-month US persistence data
68% of US adults who started tirzepatide stayed on it at six months. A claims study of 22,512 initiators shows real-world persistence outside the trial setting.
Tirzepatide in 2026 Q2: what changed
Q2 2026 brought tirzepatide maintenance data, an FDA 503B compounding proposal, and warning letters about unapproved and compounded products.
Why GLP-1 prescriptions go unfilled
About 40% of GLP-1 orders are never dispensed. Here is what the fill-rate evidence on semaglutide and tirzepatide shows, and what it cannot show.
The evolution of obesity medications
A 2026 review traces obesity drugs from withdrawn stimulants to semaglutide and tirzepatide, and sets out what the newer agents still cannot do.
Finding at-risk MASH without a liver biopsy
With semaglutide approved for MASH, finding the right patients is the bottleneck, and a new study says a liver stiffness scan can do it without a biopsy.
Peptide supplements in sports medicine
A 2026 UCLA scoping review checked six peptides sold for recovery and performance, including CJC-1295 and BPC-157, against the actual human trial evidence.
Semaglutide, Alzheimer's and mouse data
A September 2026 mouse study reports semaglutide reduced a form of hippocampal neuron death, months after the human evoke trials missed their endpoint.
GLP-1 drugs, PCOS, and trying to conceive
GLP-1 medicines such as semaglutide are not approved to treat PCOS, and current labels require stopping the drug before a planned pregnancy.
Semax in 2026 Q2: what changed
Q2 2026 gave Semax an FDA compounding review date and a public docket, while the clinical evidence base for the peptide did not move.
STEP 12: semaglutide in Chinese adults
STEP 12 tested semaglutide 2.4 mg in Chinese adults at a BMI of 24 to under 30, a band the earlier STEP obesity trials never enrolled.
Tirzepatide at 6 months: who stays on it
A US claims study of 22,512 tirzepatide starters found 68% still on the drug at six months. Here is what that number does and does not tell you.
Tirzepatide cuts liver fat despite PNPLA3
A post hoc look at SURPASS-3 MRI finds tirzepatide cut liver fat in type 2 diabetes whether or not patients carried the PNPLA3 I148M gene variant.